IBM Watson for Oncology

Watson for curing the Oncology and proved helping the physicians quickly and helps in identifying the key informations in a patient’s medical record, surface relevant evidence and explore treatment options.

Watson for Oncology combines leading oncologists’ deep expertise in cancer care with the speed of IBM Watson to help clinicians as they consider individualized cancer treatments for their patients.

Watson for Oncology is a solution that is fueled by information from relevant guidelines, best practices, and medical journals and textbooks. The solution assesses information from a patient’s medical record, evaluates medical evidence, and displays potential treatment options ranked by level of confidence, always providing supporting evidence. The oncologist can then apply their own expertise to identify the most appropriate treatment options.

Artificial intelligence (AI) has the power to transform healthcare by quickly evaluating unstructured or previously inaccessible data in medical literature or patient records. With the ability to read over 200 million pages in three seconds, IBM Watson® for Oncology is learning the language of oncology and detecting patterns that humans may not have seen. The Watson Oncology Suite of solutions integrate with existing clinical workflow and care platforms allowing users to easily surface patient-relevant attributes and information.
 

At the same time, IBM is killing off its AI collaboration tool Watson Workspace at the end of February due to low customer demand.The platform, released in its beta back in 2016, was created to host shared workspaces, collaborations and third-party apps and was essentially the legacy tech giant's answer to Slack. 

While there is no question that Watson Workspace is innovative and agile, it hasn't resonated with clients or obtained traction in the marketplace necessary for IBM to continue forward with the service. 

Sources said, IBM has stopped taking new orders for Watson Workspace and will not be adding any additional features. The memo also noted that the company is working with business partners to create options for handling subscriptions and contracts when the platform is finally put to rest.At the same time, IBM has recently developed three artificial intelligence tools that could help medical researchers fight cancer.

Now, the company has decided to make all three tools open-source, meaning scientists will be able to use them in their research whenever they wish. The tools are designed to streamline the cancer drug development process and help scientists stay on top of newly-published research - so, if they prove useful, it could mean more cancer treatments coming through the pipeline more rapidly than before.